Nosocomial infection of β-lactam antibiotic-induced vancomycin-resistant Staphylococcus aureus (BIVR)

Hososaka, Yasuko; Hanaki, Hideaki; Yanagisawa, Chie; Yamaguchi, Yuuichi; Matsui, Hidehito; Nakae, Taiji; Iwata, Satoshi; Hayashi, Izumi; Sunakawa, Keisuke

doi:10.1007/s10156-006-0455-x

Cited by 10 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pulsed-field gel electrophoresis (PFGE) analysis for MRSA isolates was performed as previously described (2,15). Briefly, bacterial cultures were grown overnight in Mueller-Hinton broth (Oxoid Ltd.) and resuspended in TN buffer (10 mM Tris, 1 M NaCl, pH 8.0).…”

Section: Methodsmentioning

confidence: 99%

“…After bacterial lysis in a lysis buffer containing 5 mg/ml lysozyme (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and 20 g/ml lysostaphin (SigmaAldrich Japan K. K.), genomic DNA was digested with SmaI (Takara Bio, Ltd.). PFGE was performed using a CHEF-DRIII system (Bio-Rad Laboratories Inc.), under the following conditions: switch time of 5.3 to 34.9 s and running time of 20 h for MRSA (15); included angle, 120°; voltage, 6 V/cm; and set temperature, 14°C.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Occurrence and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Methicillin-Resistant Staphylococcus pseudintermedius in an Academic Veterinary Hospital

Ishihara

Shimokubo

Sakagami

et al. 2010

Appl Environ Microbiol

Self Cite

View full text Add to dashboard Cite

Recently, methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus pseudintermedius (MRSP) have been increasingly isolated from veterinarians and companion animals. With a view to preventing the spread of MRSA and MRSP, we evaluated the occurrence and molecular characteristics of each in a veterinary college. MRSA and MRSP were isolated from nasal samples from veterinarians, staff members, and veterinary students affiliated with a veterinary hospital. Using stepwise logistic regression, we identified two factors associated with MRSA carriage: (i) contact with an identified animal MRSA case (odds ratio [OR], 6.9; 95% confidence interval [95% CI], 2.2 to 21.6) and (ii) being an employee (OR, 6.2; 95% CI, 2.0 to 19.4). The majority of MRSA isolates obtained from individuals affiliated with the veterinary hospital and dog patients harbored spa type t002 and a type II staphylococcal cassette chromosome mec (SCCmec), similar to the hospital-acquired MRSA isolates in Japan. MRSA isolates harboring spa type t008 and a type IV SCCmec were obtained from one veterinarian on three different sampling occasions and also from dog patients. MRSA carriers can also be a source of MRSA infection in animals. The majority of MRSP isolates (85.2%) carried hybrid SCCmec type II-III, and almost all the remaining MRSP isolates (11.1%) carried SCCmec type V. MRSA and MRSP were also isolated from environmental samples collected from the veterinary hospital (5.1% and 6.4%, respectively). The application of certain disinfection procedures is important for the prevention of nosocomial infection, and MRSA and MRSP infection control strategies should be adopted in veterinary medical practice.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Occurrence and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Methicillin-Resistant Staphylococcus pseudintermedius in an Academic Veterinary Hospital

Ishihara

Shimokubo

Sakagami

et al. 2010

Appl Environ Microbiol

Self Cite

View full text Add to dashboard Cite

show abstract

“…We reported recently that VAN-resistant MRSA emerged as a result of the simultaneous use of VAN and ␤-lactam antibiotics (15,26). A hospital outbreak of BIVR infection was reported previously (16). However, it is not known whether or not the mechanism of VAN resistance in the BIVR cells is similar to those of previously reported VAN-resistant MRSA isolates such as Mu50.…”

Section: Discussionmentioning

confidence: 93%

Rapid Depletion of Free Vancomycin in Medium in the Presence of β-Lactam Antibiotics and Growth Restoration in Staphylococcus aureus Strains with β-Lactam-Induced Vancomycin Resistance

Yanagisawa

Hanaki

Matsui

et al. 2009

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

Growth of the BIVR cells to an absorption level of ϳ0.3 at 578 nm required about 24 h in the presence of vancomycin alone at the MIC (4.0 g/ml). However, growth was achieved in only about 10 h when 1/1,000 to 1/2,000 the MIC of ␤-lactam antibiotic was added 2 h prior to the addition of vancomycin, suggesting that the ␤-lactams shortened the time to recovery from vancomycin-mediated growth inhibition. Free vancomycin in the culture medium decreased to 2.3 g/ml in the first 8 h in the culture containing vancomycin alone, yet cell growth was undetectable. When the vancomycin concentration dropped below ϳ1.5 g/ml at 24 h, the cells began to grow. In the culture supplemented with the ␤-lactam 2 h prior to the addition of vancomycin, the drug concentration continuously dropped from 4 to 0.5 g/ml in the first 8 h, and the cells began to grow at a vancomycin concentration of ϳ1.7 g/ml or at 4 h of incubation. The gene encoding the enzyme involved in D-Ala-D-lactate synthesis was undetectable. Based on these results, we concluded that BIVR is attributable mainly to a rapid depletion of vancomycin in the medium triggered or promoted by ␤-lactam antibiotics.

show abstract

“…104 Infections with VRE are prevalent in onco-hematological and HSCT patients in some countries [105][106][107][108][109][110] but, until now, infections with VISA or hVISA remain rare in this patient population. [111][112][113] Agents showing activity against some glycopeptide non-susceptible Gram-positive pathogens include linezolid, daptomycin, quinupristin/dalfopristin, tigecycline and fosfomycin, as well as the new agents telavancin and ceftaroline. The exact spectra of these agents vary and should be considered before use.…”

Section: Resistant Gram-positive Pathogensmentioning

confidence: 99%

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

et al. 2013

View full text Add to dashboard Cite

The detection of multi-resistant bacterial pathogens, particularly those to carbapenemases, in leukemic and stem cell transplant patients forces the use of old or non-conventional agents as the only remaining treatment options. These include colistin/polymyxin B, tigecycline, fosfomycin and various anti-gram-positive agents. Data on the use of these agents in leukemic patients are scanty, with only linezolid subjected to formal trials. The Expert Group of the 4 th European Conference on Infections in Leukemia has developed guidelines for their use in these patient populations. Targeted therapy should be based on (i) in vitro susceptibility data, (ii) knowledge of the best treatment option against the particular species or phenotype of bacteria, (iii) pharmacokinetic/pharmacodynamic data, and (iv) careful assessment of the risk-benefit balance. For infections due to resistant Gram-negative bacteria, these agents should be preferably used in combination with other agents that remain active in vitro, because of suboptimal efficacy (e.g., tigecycline) and the risk of emergent resistance (e.g., fosfomycin). The paucity of new antibacterial drugs in the near future should lead us to limit the use of these drugs to situations where no alternative exists. ABSTRACT © F e r r a t a S t o r t i F o u n d a t i o n 2 0 1 3organizing committee and experts were solicited to form the working group. The group reviewed the published English-language literature and prepared proposals on treatment options for infections due to resistant bacteria. Papers for review were sought using PubMed with the terms "linezolid", "daptomycin", "quinupristin/ dalfopristin", "colistin or polymyxin", "tigecycline", "fosfomycin", "telavancin", "ceftaroline" AND "stem cell transplantation or bone marrow transplant or leukemia or hematological malignancy or cancer". References cited in the articles identified were also considered. In respect of 'Duration of therapy', the main search terms used were "antibiotic therapy"; "stem cell transplantation or bone marrow transplantation or hematological malignancy or cancer"; "febrile neutropenia" and "duration therapy", "discontinuation antibiotics" and "microbiologically documented infection". Definitions of resistanceA bacterial isolate was considered non-susceptible if it was categorized resistant, intermediate or non-susceptible when using clinical breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST), Clinical and Laboratory Standards Institute (CLSI) or the US Food and Drug Administration (FDA). Definitions of 'MDR' vary among authors and usually presume resistance to at least two antibiotics used in empiric therapy (3 rd 4 th -generation cephalosporins, carbapenems or piperacillin/tazobactam) or resistance to at least three of the following antibiotic classes: antipseudomonal penicillins, cephalosporins, carbapenems, aminoglycosides and fluoroquinolones. [11][12][13][14][15] According to the recent definition of the European Centre for Disease Prevention and Control...

show abstract

Nosocomial infection of β-lactam antibiotic-induced vancomycin-resistant Staphylococcus aureus (BIVR)

Cited by 10 publications

References 14 publications

Occurrence and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Methicillin-Resistant Staphylococcus pseudintermedius in an Academic Veterinary Hospital

Occurrence and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Methicillin-Resistant Staphylococcus pseudintermedius in an Academic Veterinary Hospital

Rapid Depletion of Free Vancomycin in Medium in the Presence of β-Lactam Antibiotics and Growth Restoration in Staphylococcus aureus Strains with β-Lactam-Induced Vancomycin Resistance

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

Contact Info

Product

Resources

About